A targeted drug delivery system developed at Rutgers University could possibly make ovarian cancer more treatable. The study results published in Clinical Cancer Research also indicated the new system could increase survival rates in ovarian cancer. Read the full article here.
Research funded by Ovarian Cancer Research Fund shows that adipose derived stromal cells derived from the human omentum can promote ovarian cancer proliferation, migration, chemoresistance and radiation resistance in-vitro. The research, funded in part through an OCRF grant to senior author Ann Klopp, MD, PhD was published online last week in PLoS One. The researchers hypothesized … Continued
A team of current and former OCRF grantees at Brigham and Women’s Hospital, Harvard Medical School and Dana-Farber Cancer Institute has developed genetically engineered mouse models of high-grade serous ovarian cancer that shed light on the pathogenesis of ovarian cancer for BRCA1/2 mutation carriers. These models, which target the cell of origin (fallopian tube secretory cells) and recreate key genetic … Continued
George Preti, who works at the Monell Chemical Senses Center as an organic chemist, and an interdisciplinary team that includes physicists and veterinarians at the University of Pennsylvania are using an electronic box to explore whether cancer has a smell. In diseases that affect our metabolism, we secrete smells that can be indicative of what … Continued
New research funded in part by OCRF has shown that combining microRNA and siRNAs may be an effective new approach to developing better targeted therapies for ovarian cancer. The research was reported in the November 2013 issue of Cancer Discovery, where the findings were also highlighted in an editorial commentary. The research was funded in … Continued
Research published in the November 2013 issue of Gynecologic Oncology reports that the use of the chemoresponse assay ChemoFx can lead to improved clinical outcomes for women undergoing treatment for ovarian cancer. The goal of this clinical trial, which took nearly ten years to complete, was to determine the association of chemoresponse assay results with … Continued
An international group of researchers examined quality of life factors for ovarian cancer patients enrolled in a large European clincial trial (EORTC 55971). They compared the quality of life patients who had primary debulking surgery versus those who had neo-adjuvant chemotherapy, followed by surgery. The results, which are published in the journal Gynecologic Oncology, showed … Continued
Oregon State University researchers have found that using nanotechnology with heat and cytotoxic drugs can kill up to 95% of ovarian cancer cells. While there is still additional research that needs to be done, the results of the initial study are promising for the future of ovarian cancer treatments. Read full article here.
A new study released in Lancet Oncology showed that abnormal levels of female hormones in the bloodstream may be why women with BRCA1 or BRCA2 mutations are at a higher risk for breast and ovarian cancer and not other cancers. UCL Department of Women’s Cancer completed the study that found different levels of the female hormones … Continued
A new study conducted by Cancer Research UK has identified chemical “tags” on DNA in patients’ tumors that could help doctors decide the type of chemotherapy women with advanced ovarian cancer should receive. The research was published in Clinical Cancer Research. These tags, known as epigenetic markers, could be used to assess whether patients will … Continued
A study led by Dr. Andrew Stephens from the Prince Henry’s Institute has discovered a process that is associated with inflammation in cancers. This discovery could lead to expanded treatment options for some types of ovarian cancer tumors. Monash Health, Hasanuddin University, Indonesia and Lincoln Research Centre, Christchurch also participated in the study which was … Continued
The European Cancer Congress convened in Amsterdam, the Netherlands from September 27 – October 1, 2013. The European Cancer Congress in the main multidisciplinary and multi-professional educational meeting in oncology to take place in Europe. At ECCO, cancer specialists from around the world convene to present their research. In this story on Medscape, Dr. Stanley … Continued
Get email updates about research news, action alerts, and ways to join the fight.
